China drug licensing deals surge nearly 10-fold in value since 2021
Source: SeekingAlpha
2026-02-19 13:31:04 ET
More on AbbVie, AstraZeneca PLC, etc.
- Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
- Pfizer: The Rebound Looks Unsustainable
- AbbVie: Dominating Immunology While Building Oncology Upside
- Merck posts new Enflonsia RSV data in infants
- Merck reports positive phase 3 second-season RSV data for ENFLONSIA
Read the full article on Seeking Alpha
For further details see:
China drug licensing deals surge nearly 10-fold in value since 2021
Astellas Pharma Inc. ADR
NASDAQ: ALPMY
ALPMY Trading
-0.89% G/L:
$14.75 Last:
104,314 Volume:
$15.43 Open:
ALPMY Latest News
January 08, 2026 10:30:00 am
VYLOY(TM) (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
December 17, 2025 06:45:00 am
PADCEV(TM) Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 10, 2025 06:30:00 pm
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
ALPMY Stock Data
$29,447,472,947
1,772,218,737
N/A
5
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
